uniQure N.V. (QURE) Dividend History

uniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.

Paasheuvelweg 25a, Amsterdam, P7, 1105 BP
Phone: 1-339-970-7000
Website: https://www.uniqure.com

Dividend History

uniQure N.V. currently does not pay dividends

Company News

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

uniQure, a gene therapy company, has appointed Kylie O'Keefe as Chief Customer and Strategy Officer to lead the commercialization of its investigational gene therapy AMT-130 for the treatment of Huntington's disease.

GlobeNewswire Inc.
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's gene therapy HEMGENIX has shown sustained efficacy and safety in treating adults with hemophilia B, with 94% of patients remaining free of continuous prophylaxis treatment four years after a single infusion.

Benzinga
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research
Why Shares of uniQure Are Up Thursday

The company announced a reorganization that included layoffs.

The Motley Fool

Page data last updated 07/23/2025 18:14:31 UTC